Manufacturing / Biological Products, Except Diagnostic Substances
aTYR PHARMA INC
ATYR
$0.25
$0.00 (-0.80%)
Price as of Oct 9, 2026 16:51 UTC
52 M
Market Cap (Micro Cap)
Nov 04
Next Earnings
Technical Signals
as of Oct 7
Bearish
0 of 7
Trend
- Above 20-day average $0.34
- Above 50-day average $0.42
- Above 200-day average $0.62 · -55.1%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) —
- Momentum cross (20/50) Down · 102d ago
Volume
- Below-average volume 0.1x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Heat Map
Delta-risk grid for ATYR options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
3 buys
3 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Oct 01, 2026 | Yaras Brandon | Grant | 410,000 | $0 | -10.3% | |
| May 27, 2026 | SCHIMMEL PAUL | Other | 100,000 | $49,630 | -47.6% | |
| May 27, 2026 | SCHIMMEL PAUL | Buy | 100,000 | $49,630 | -47.6% | |
| May 11, 2026 | Gross Jane A | Other | 50,000 | $0 | -72.6% | |
| May 11, 2026 | BENEVICH ERIC | Other | 50,000 | $0 | -72.6% | |
| May 11, 2026 | SCHIMMEL PAUL | Other | 50,000 | $0 | -72.6% | |
| May 11, 2026 | BENEVICH ERIC | Grant | 50,000 | $0 | -72.6% | |
| May 11, 2026 | Lucas Svetlana | Grant | 50,000 | $0 | -72.6% | |
| May 11, 2026 | Gross Jane A | Grant | 50,000 | $0 | -72.6% | |
| May 11, 2026 | Zaknoen Sara | Grant | 50,000 | $0 | -72.6% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 12, 2026 | Q2 2026 | -$0.12 | |||
| Aug 05, 2026 | Q2 2026 | -$0.12 | |||
| Mar 31, 2026 | Q1 2026 | -$0.14 | -$0.11 | +21.6% | Beat |
| Dec 31, 2025 | Q4 2025 | -$0.19 | -$0.14 | +25.3% | Beat |
| Sep 30, 2025 | Q3 2025 | -$0.19 | -$0.26 | -38.8% | Miss |
| Jun 30, 2025 | Q2 2025 | -$0.19 | -$0.22 | -17.0% | Miss |
| Mar 31, 2025 | Q1 2025 | -$0.19 | -$0.17 | +12.3% | Beat |
Track ATYR with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for ATYR and your entire portfolio.